Literature DB >> 16416186

Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study.

Emilio D'Amico1, Caterina Chincoli, Pierluigi Cacciatore, Gabriella di Pasqua, Luana Cosentino, Giuseppe Riario-Sforza, Ernesta Pennese, Fabio Capani, Carlo Palazzi.   

Abstract

The clinical spectrum of mixed cryoglobulinemia embraces several manifestations: recurrent vascular purpura, weakness, arthralgia/arthritis, glomerulonephritis, peripheral neuropathies, and Raynaud's phenomenon. Mixed cryoglobulinemia is currently treated with steroids, low-antigen content diet, immunosuppressors, plasma exchange, and antiviral therapy, namely, alpha -interferon alone or, more recently, in association with ribavirin. In the present research, we verified the effectiveness of combined therapy with interferon and ribavirin on asymptomatic mixed cryoglobulinemia in naïve (never treated before) patients with chronic hepatitis C. We enrolled 50 consecutive patients, 31 males and 19 females, with chronic hepatitis C who showed a sustained response to combined antiviral therapy (interferon and ribavirin). Before treatment, cryoglobulins were detected in 25 subjects (50%). Only 1 of the 25 patients with asymptomatic mixed cryoglobulinemia had persistence of cryoglobulins at the end of the follow-up period. Unexpectedly, in 7 of 25 subjects without mixed cryoglobulinemia before treatment, cryoglobulins became detectable after antiviral therapy. Our present study first reports the onset of asymptomatic mixed cryoglobulinemia in hepatitis C virus patients after clearance of the virus from blood obtained with a combined antiviral treatment. Possible explanations are discussed. Our data also suggest that the appearance of a clinically evident mixed cryoglobulinemia cannot be excluded in this kind of subject.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16416186     DOI: 10.1007/s10620-005-3059-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Mixed cryoglobulinemia secondary to interferon therapy for hepatitis C: case report & review of the literature.

Authors:  Arash Kimyai-Asadi; Kathy Gohar; Pil Kang; Adil Usman; Robert Zenenberg; Ming H Jih
Journal:  J Drugs Dermatol       Date:  2002-07       Impact factor: 2.114

2.  Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha.

Authors:  E Zuckerman; D Keren; G Slobodin; I Rosner; M Rozenbaum; E Toubi; E Sabo; I Tsykounov; J E Naschitz; D Yeshurun
Journal:  J Rheumatol       Date:  2000-09       Impact factor: 4.666

3.  Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia.

Authors:  C Donada; A Crucitti; V Donadon; L Chemello; A Alberti
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

4.  The benefit of long-term interferon alfa therapy for symptomatic mixed cryoglobulinemia (cutaneous vasculitis/membranoproliferative glomerulonephritis) associated with chronic hepatitis C infection.

Authors:  R A Willson
Journal:  J Clin Gastroenterol       Date:  2001-08       Impact factor: 3.062

5.  Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  G Garini; L Allegri; L Carnevali; W Catellani; P Manganelli; C Buzio
Journal:  Am J Kidney Dis       Date:  2001-12       Impact factor: 8.860

Review 6.  Cryoglobulinemia vasculitis.

Authors:  Patrice Cacoub; Nathalie Costedoat-Chalumeau; Olivier Lidove; Laurent Alric
Journal:  Curr Opin Rheumatol       Date:  2002-01       Impact factor: 5.006

7.  Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.

Authors:  J L Calleja; A Albillos; R Moreno-Otero; I Rossi; G Cacho; F Domper; M Yebra; P Escartín
Journal:  Aliment Pharmacol Ther       Date:  1999-09       Impact factor: 8.171

8.  Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon.

Authors:  Cesare Mazzaro; Francesca Zorat; Consuelo Comar; Fabiana Nascimben; Dario Bianchini; Stefano Baracetti; Carlo Donada; Valter Donadon; Gabriele Pozzato
Journal:  J Rheumatol       Date:  2003-08       Impact factor: 4.666

9.  Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C.

Authors:  Tram N Q Pham; Sonya A MacParland; Patricia M Mulrooney; Helen Cooksley; Nikolai V Naoumov; Tomasz I Michalak
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  [Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome].

Authors:  P Fadda; L La Civita; A L Zignego; C Ferri
Journal:  Reumatismo       Date:  2002 Oct-Dec
View more
  3 in total

1.  Treatment of hepatitis C cryoglobulinemia: mission and challenges.

Authors:  Zeid Kayali; Douglas R Labrecque; Warren N Schmidt
Journal:  Curr Treat Options Gastroenterol       Date:  2006

2.  Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection.

Authors:  Jonathan Moorman; Zhi P Dong; Lei Ni; Chunlan Zhang; Thomas Borthwick; Zhi Q Yao
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

3.  Differential regulation of SOCS-1 signalling in B and T lymphocytes by hepatitis C virus core protein.

Authors:  Zhi Qiang Yao; Deborah Prayther; Christopher Trabue; Zhi Ping Dong; Jonathan Moorman
Journal:  Immunology       Date:  2008-04-04       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.